101
4
Coppen, A. & Bailey, J., “Enhancement of the Antidepressant Action of Fluoxetine by Folic Acid: A Randomized,
Placebo-controlled Trial,” Journal of Affective Disorders 60(2):121-130 (2000).
http://www.ncbi.nlm.nih.gov/pubmed/10967371
(^5) Alpert, J.E., Papakostas, G.I., and Mischoulon, D., “One-carbon Metabolism and the Treatment of Depression:
Roles of S-Adenosyl-L-Methionine and Folate,” in Mischoulon and Rosenbaum, Natural Medications for Psychiatric
Disorders: Considering the Alternatives (2002/2008), Second Edition Copyright 2008 by Lippincott Williams &
Wilkins (Philadelphia), at 75.
(^6) Gilbody, S., Lightfoot, T. & Sheldon, T., “Is Low Folate a Risk Factor for Depression? A Meta-analysis and
Exploration of Heterogeneity,”Journal of Epidemiological Community Health 6 1:631-637 (2007).
(^7) Bjelland, I., Tell, G.S.,, Vollset, S.E., et al., “Folate, Vitamin B-12, Homocysteine and the MTHFR 677C->T
Polymorphism in Anxiety and Depression: The Hordaland Homocysteine Study,” Archives of General Psychiatry
60:618-626 (2003).
(^8) Papakostas, G.I., Petersen, T., Lebowitz, B.D., et al. “The Relationship Between Serum Folate, Vitamin B-12, and
Homocysteine Levels in Major Depressive Disorder and the Timing of Improvement with Fluoxetine,” Int. J.
Neuropsycho. Pharmacol. 8:523-528 (2005).
(^9) Godfrey, P.S., Toone, B.K., Carney, M.W., et al., “Enhancement of Recovery from Psychiatric Illness by
Methylfolate,” Lancet 336:392-395 (1990).
(^10) Alpert, J.E., Mischoulon, D., Rubenstein, G.E.F., et al., “Folinic Acid as an Adjunctive Treatment for SSRI-refractory
Depression,” Ann. Clinical Psychiatry 14:33-38 (2002).
(^11) Fava, M. & Mischoulon, D., “Folate in Depression: Efficacy, Safety, Differences in Formulations, and Clinical
Issues,” J. Clin. Psychiatry, 70 Suppl. 5: 12 - 7.
(^12) Muskin, P.R., Gerbarg, P.L., and Brown, R.P., Complementary and Integrative Therapies for Psychiatric Disorders,
Psychiatric Clinics of North America, copyright Elsevier, Inc., Philadelphia ( 2013 ) (“Brown et al. II”) at 4.
(^13) Lake, J.A. and Spiegel, D., Complementary and Alternative Treatments in Mental Health Care, American
Psychiatric Publishing, Inc., Washington (2007), at 123.
(^14) Weil, A., Spontaneous Happiness (Little, Brown and Company, New York 2011) at 204.
(^15) Brown et al., op. cit., at 147.
(^16) Brown et al. II, op. cit., at 6.
(^17) Overcoming the difficulty of delivering therapeutic agents to specific regions of the brain presents a major
challenge to treatment of most brain disorders. In its neuroprotective role, the blood–brain barrier functions to
hinder the delivery of many potentially important diagnostic and therapeutic agents to the brain. Therapeutic
molecules and genes that might otherwise be effective in diagnosis and therapy do not cross the BBB in adequate
amounts. Mechanisms for drug targeting in the brain involve going either "through" or "behind" the BBB.
(^18) J. Clinical Psychiatry 70:5 (May, 2009).